
ID/ASP PharmD | Brooklyn, NY | PGY-2 Infectious Diseases @sunydownstate | PGY-1 @maimopharmres #TwitteRx #IDTwitter Views/Tweets are my own.
Joined February 2022
- Tweets298
- Following243
- Followers153
- Likes1.2K
Daniel Rampersad, PharmD, BCIDP retweeted
🆕🔥 Review Article @PharmacoJournal
by many 🌟s @SERGE_45_ABX @BBookstaver_USC @blandman19
A review of antibiotic safety in pregnancy —2025 update #IDXposts
accpjournals.onlinelibrary.w…
Daniel Rampersad, PharmD, BCIDP retweeted
Still using clindamycin for necrotizing SSTIs? Time to consider the switch to linezolid:
🦠Similar toxin inhibition
💩 Better AE profile (⬇️ C. Diff )
2 for 1: no vancomycin (🙅♀️ AKI)
🧫No ⬆️ resistance @MGottliebMD @AnnalsofEM sciencedirect.com/science/ar…
Daniel Rampersad, PharmD, BCIDP retweeted
Effects of cancer therapy on AMR
Cisplatin➡️cross-resistance to FQ (target bacterial DNA)
Methotrexate➡️dihydrofolate reductase mutations➡️co-select for β-lactams/AG/fosfo resistance
Anthracyclines➡️efflux pump expression
Etoposide➡️oxidative stress➡️gyrA mutations
doi.org/10.1016/j.lanmic.202…
Daniel Rampersad, PharmD, BCIDP retweeted
Switching to an oral azole (fluconazole or voriconazole) is moderately recommended after 5 or more days of echinocandin treatment in patients meeting the following criteria 👇 #idxposts
🔥Just published🔥 @TheLancetInfDis @CornelyOliver
@RosanneSprute
Global guideline for the diagnosis and management of candidiasis: an an initiative of the @eurconfmedmycol in cooperation with @ISHAM_Mycology & @ASMicrobiology
thelancet.com/journals/lanin…
Daniel Rampersad, PharmD, BCIDP retweeted
journals.asm.org/doi/10.1128… Nice!!!
Daniel Rampersad, PharmD, BCIDP retweeted
MYCOPLASMA PNEUMONIAE
This cheeky little intracellular bacteria seems to be up to mischief with kids in the USA at the moment
A quick thread on this bug, what's going on, and what to do (or not do!) about it
1/🧵
Daniel Rampersad, PharmD, BCIDP retweeted
Replying to @IDstewardship
Linezolid is superior (not just non inferior) to vancomycin for SSTI.
pubmed.ncbi.nlm.nih.gov/3414…
Daniel Rampersad, PharmD, BCIDP retweeted
1/2 Dr. Shruti Gohil @UCIrvineHealth presented INSPIRE data on intra-abdominal infections (IAIs) at #IDWeek2024. IAIs involve diverse organs/spaces. Yet, only 1% (+) for MRSA and another 1% (+) for Pseudomonas, despite 63% of patients getting empiric broad-spectrum abx treatment.
Daniel Rampersad, PharmD, BCIDP retweeted
More is not always better. Adding vancomycin to cefazolin as surgical prophylaxis in patients undergoing arthroplasty does not improve outcomes in patients not known to be MRSA colonized. Outcomes WORSE for knee arthroplasty. Just don't. nejm.org/doi/10.1056/NEJMoa2… #IDWeek2024
Daniel Rampersad, PharmD, BCIDP retweeted
Good board review on Candida treatment. #IDWeek2024
Daniel Rampersad, PharmD, BCIDP retweeted
Replying to @IDPharmD_Kate
@IDPharmD_Kate crushing it & getting everyone talking about, is this really AKI when it comes to vanco + pip/tazo? And coining the term fake-KI 🤩 Her key lesson…we probably don’t need vanco (or pip/tazo) for most patients! #IDWeek2024 #SIDP2024
Daniel Rampersad, PharmD, BCIDP retweeted
Me on ICU rounds when someone says we can’t use linezolid because the patient is on an SSRI
Daniel Rampersad, PharmD, BCIDP retweeted
It's your favorite post of the month- the articles of interest for August! With a few from June and July 😊🦠
Learned something new today 😳
Replying to @EM_RESUS
Used to see this at the VA years ago. Some hospitals used ping pong balls to treat tuberculosis (TB) by inserting them into a patient's chest cavity- plombage.
If I'm wrong, I'll try to stick to cardiology 🤷
2
69
Daniel Rampersad, PharmD, BCIDP retweeted
If you’re wondering, “But wait, how do I know the pre-test probability for bacteremia in common infectious diseases?” Well, @ValeriaFabreMD covers some of these in this must-read scoping review!
academic.oup.com/cid/article…
Now that we’re on the topic: Isolated fever is a POOR predictor of bacteremia. Shaking chills are better indicators. HOWEVER, you also need to consider the pre-test probability based on the syndrome in question.
jamanetwork.com/journals/jam…
Daniel Rampersad, PharmD, BCIDP retweeted
💩 additional evidence that cefepime causes more CDiff than piptazo
💩theoretically piptazo has anaerobic coverage so you might assume that it should cause more CDiff.. but it doesn't
💩 this is why we need EBM, not handwaving about saving the anaerobes
sciencedirect.com/science/ar…
Daniel Rampersad, PharmD, BCIDP retweeted
It's here! 100th #Breakpoints Episode:
Drs. Jeffrey Pearson & Jason Pogue join Dr. Jeannette Bouchard as they take on all things tetracyclines. Do not miss this one! This podcast was supported by an unrestricted grant from Paratek Pharmaceuticals Inc.
🎧 sidp.pinecast.co
Daniel Rampersad, PharmD, BCIDP retweeted
Yesterday, at the International AIDS Conference (#AIDS2024) in Munich, we got one of those thrilling moments you hope for when attending a scientific conference -- but don't usually get!
Here's what happened. @LindaGailBekker @drmoupali
blogs.jwatch.org/hiv-id-obse…
Daniel Rampersad, PharmD, BCIDP retweeted
Replying to @ABsteward
Most often, the best « agent » against S.maltophilia is a good I.D. doc who says « this is not an infection, it’s colonization (probably selected because of the unjustified ATB overuse over the last few weeks »)




































